Tamer L, Tanriverdi K, Ercan B, Unlu A, Sucu N, Pekdemir H, Atik U
Department of Biochemistry, Faculty of Medicine, Mersin University, Mersin, Turkey.
East Mediterr Health J. 2004 Jan-Mar;10(1-2):125-30.
Point mutations in the receptor binding domain of low density lipoprotein may increase cholesterol levels in blood. Three mutations of Apo B-100 protein result in defective binding (Arg 3500 ----> [corrected] Gln, Arg 3500 ----> [corrected] Trp and Arg 3531 ----> [corrected] Cys). We estimated the frequency of Apo B point mutations (codon 3500) C9774T (Arg 3500 ----> [corrected] Trp) and G9775A (Arg 3500 ----> [corrected] Gln) in 179 atherosclerotic, 145 hyperlipidaemic individuals and 272 healthy individuals in the east Mediterranean region of Turkey. Lipid and lipoprotein levels were measured with routine biochemical analyser and Apo B mutation was detected using real-time PCR. Neither mutation was found. In this region, Apo B-100 protein mutations are rare and causes of hyperlipidaemia and atherosclerosis may therefore be unrelated to them.
低密度脂蛋白受体结合域中的点突变可能会使血液中的胆固醇水平升高。载脂蛋白B-100蛋白的三种突变会导致结合缺陷(精氨酸3500 ----> [校正后]谷氨酰胺、精氨酸3500 ----> [校正后]色氨酸和精氨酸3531 ----> [校正后]半胱氨酸)。我们估算了土耳其东地中海地区179名动脉粥样硬化患者、145名高脂血症患者及272名健康个体中载脂蛋白B点突变(密码子3500)C9774T(精氨酸3500 ----> [校正后]色氨酸)和G9775A(精氨酸3500 ----> [校正后]谷氨酰胺)的发生频率。使用常规生化分析仪测量血脂和脂蛋白水平,并通过实时聚合酶链反应检测载脂蛋白B突变。未发现任何一种突变。在该地区,载脂蛋白B-100蛋白突变很少见,因此高脂血症和动脉粥样硬化的病因可能与这些突变无关。